EMA Authorised: Fabrazyme (agalsidase beta) — Sanofi B.V.

View source ↗

Summary

The European Medicines Agency authorised Fabrazyme (agalsidase beta) for Fabry disease, with Sanofi B.V. as the marketing authorization holder, decision dated 3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)

Snippet

Status: Authorised. Therapeutic area: Fabry Disease. MAH: Sanofi B.V.. Decision date: 30/07/2024